Clinical Trials List
Protocol NumberCBYL719X2104
2013-01-01 - 2016-12-31
Phase I/II
Terminated3
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- HUAI-CHENG HUANG Division of Hematology & Oncology
- JO-PAI CHEN Division of Hematology & Oncology
- YA-FANG CHEN Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Li-Yu Lee Division of Others -
- Shu-Hang Ag Division of Radiology
- Cheng-Lung Hsu Division of Hematology & Oncology
- Tung-Chieh Chang Division of Radiation Therapy
- 廖俊達 Division of Hematology & Oncology
- Tzu-Chen Yen Division of Nuclear Medicine
- Chia-Hsun Hsieh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 張俊彥 Division of Hematology & Oncology
- Yu-Min Yeh Division of Hematology & Oncology
- Wu-Chou Su Division of Hematology & Oncology
- Sen-Tien Tsai Division of Otolaryngology
- Kwang-Yu Chang Division of Hematology & Oncology
- 莊明宗 Division of Radiology
- Shang-Yin Wu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
111 participants
